

# Divarasib plus cetuximab in *KRAS G12C*-positive colorectal cancer: a phase 1b trial

Received: 18 October 2023

Accepted: 9 November 2023

Published online: 5 December 2023

 Check for updates

A list of authors and their affiliations appears at the end of the paper


*KRAS G12C* mutation is prevalent in ~4% of colorectal cancer (CRC) and is associated with poor prognosis. Divarasib, a *KRAS G12C* inhibitor, has shown modest activity as a single agent in *KRAS G12C*-positive CRC at 400 mg. Epidermal growth factor receptor has been recognized as a major upstream activator of RAS–MAPK signaling, a proposed key mechanism of resistance to *KRAS G12C* inhibition in CRC. Here, we report on divarasib plus cetuximab (epidermal growth factor receptor inhibitor) in patients with *KRAS G12C*-positive CRC ( $n = 29$ ) from arm C of an ongoing phase 1b trial. The primary objective was to evaluate safety. Secondary objectives included preliminary antitumor activity. The safety profile of this combination was consistent with those of single-agent divarasib and cetuximab. Treatment-related adverse events led to divarasib dose reductions in four patients (13.8%); there were no treatment withdrawals. The objective response rate was 62.5% (95% confidence interval: 40.6%, 81.2%) in *KRAS G12C* inhibitor-naïve patients ( $n = 24$ ). The median duration of response was 6.9 months. The median progression-free survival was 8.1 months (95% confidence interval: 5.5, 12.3). As an exploratory objective, we observed a decline in *KRAS G12C* variant allele frequency associated with response and identified acquired genomic alterations at disease progression that may be associated with resistance. The manageable safety profile and encouraging antitumor activity of divarasib plus cetuximab support the further investigation of this combination in *KRAS G12C*-positive CRC. ClinicalTrials.gov identifier: [NCT04449874](https://clinicaltrials.gov/ct2/show/study/NCT04449874)

The Kirsten rat sarcoma virus oncogene homologue (*KRAS*) protein is a guanosine triphosphatase (GTPase) that cycles between the active GTP-bound and inactive GDP-bound states to regulate cell proliferation, migration and survival<sup>1,2</sup>. The glycine-to-cysteine mutation at position 12 (p.Gly12Cys) of the *KRAS* protein favors the active GTP-bound state, increasing downstream oncogenic signaling and uncontrolled cell growth. Oncogenic *KRAS G12C* mutations occur in ~4% of patients with CRC, and are associated with poor prognosis<sup>3–7</sup>. Patients with CRC who have tumors harboring a *KRAS* mutation (including *KRAS G12C*) do not benefit and thus are not eligible for anti-epidermal growth factor receptor-based therapies<sup>8,9</sup>.

Divarasib (GDC-6036) is an orally bioavailable, covalent *KRAS G12C* inhibitor that turns off its oncogenic signaling by irreversibly locking the protein in an inactive state. In vitro studies have also shown that divarasib is 5 to 20 times as potent and up to 50 times as selective as compared to the *KRAS G12C* inhibitors sotorasib and adagrasib<sup>10</sup>. Single-agent divarasib treatment at 400 mg achieved a confirmed objective response rate (ORR) of 56.4% in patients with non-small cell lung cancer and 35.9% in patients with CRC, with a median progression-free survival (PFS) of 13.1 and 6.9 months, respectively<sup>11</sup>.

Despite the encouraging antitumor activity with single-agent divarasib in patients with CRC, adaptive feedback reactivation of RAS–MAPK signaling, a proposed key mechanism of resistance to *KRAS G12C*

✉ e-mail: [jayesh.desai@petermac.org](mailto:jayesh.desai@petermac.org); [saewon1@snu.ac.kr](mailto:saewon1@snu.ac.kr)



**Fig. 1 | Patient disposition.** Patient disposition for all 29 patients that were enrolled and received divarasisib plus cetuximab.

inhibition in CRC, occurs frequently and ultimately limits efficacy<sup>12–14</sup>. Preclinical studies have identified EGFR as a major mediator of adaptive feedback, and concomitant blockade of EGFR has been shown to enhance the antitumor activity of KRAS G12C inhibition<sup>12,15</sup>. Therefore, the combination of an EGFR inhibitor with a KRAS G12C inhibitor may more effectively inhibit the KRAS–MAPK pathway, prevent adaptive feedback and lead to more robust clinical responses. Clinical studies of other KRAS G12C inhibitors, such as sotorasib and adagrasib, support this hypothesis, with higher response rates observed when used in combination with an EGFR inhibitor compared to when used as single-agent treatment in patients with CRC<sup>16–20</sup>.

Divarasisib in combination with other anticancer therapies is currently being evaluated in an ongoing phase 1b study in patients with advanced or metastatic solid tumors harboring a *KRAS G12C* mutation. Here, we report results from arm C patients with CRC who received divarasisib in combination with cetuximab, an EGFR inhibitor. The primary objective of this study was to evaluate safety; secondary objectives included characterization of preliminary antitumor activity and the pharmacokinetic profile, and exploratory objectives included the characterization of biomarkers of response and resistance.

## Results

### Patient disposition and baseline demographics

A total of 29 patients were enrolled into arm C from 17 sites in 10 countries between 28 July 2021 and 07 October 2022 (Fig. 1). Key inclusion criteria were CRC with documentation of the *KRAS G12C* mutation from either central testing of blood samples (FoundationOne Liquid CDx/FILCDx) or local testing of tumor tissue or blood samples (using a validated molecular testing method) and evaluable or measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Patients with prior KRAS G12C inhibitor treatment must not have discontinued due to toxicity related to the prior KRAS G12C inhibitor. Key exclusion criteria were active, untreated central nervous system (CNS) metastases (previously treated CNS metastases were allowed); treatment with another anticancer therapy within 3 weeks or five half-lives before initiation of study treatment, whichever is shorter; and radiation therapy as cancer therapy within 4 weeks before initiation of divarasisib.

Patients received oral divarasisib at 200 mg ( $n = 3$ ) or 400 mg ( $n = 26$ ) once daily, plus intravenous cetuximab (400 mg/m<sup>2</sup> on cycle 1 day 1 (CID1) only, then 250 mg/m<sup>2</sup> once weekly) in 21-d cycles. The selected expansion dose for the divarasisib combination with cetuximab was 400 mg and ongoing dose investigations are still occurring in other combinations. The data cutoff date was 01 April 2023 with an enrollment cutoff of 07 October 2022. This analysis included patients who received at least one dose of divarasisib and cetuximab. The median time

**Table 1 | Baseline demographics and disease characteristics**

	All patients (N=29)
Median age (range), years	59 (33–87)
Female, n (%)	15 (51.7)
Race, n (%)	
White	20 (69.0)
Asian	6 (20.7)
Multiple	1 (3.4)
Unknown	2 (6.9)
ECOG, n (%)	
0	16 (55.2)
1	13 (44.8)
Location of tumor, n (%)	
Left side	18 (62.1)
Right side <sup>a</sup>	9 (31.0)
Unknown	2 (6.9)
Prior systemic therapies, n (%)	
1	5 (17.2)
2	10 (34.5)
3	4 (13.8)
≥4	10 (34.5)
Prior 5-FU/capecitabine, n (%)	29 (100.0)
Prior oxaliplatin, n (%)	27 (93.1)
Prior irinotecan, n (%)	24 (82.8)
Prior bevacizumab, n (%)	24 (82.8)
Prior KRAS G12C inhibitor, n (%)	5 (17.2)

<sup>a</sup>‘Right side’ includes tumor location reported as both right side and midline. ECOG, Eastern Cooperative Oncology Group.

on divarasisib treatment was 7.1 months (range: 2.6–12.6), and on cetuximab treatment was 6.7 months (range: 0.5–12.2). Study treatment was discontinued in 20 patients (69.0%), with the reasons being progressive disease according to RECIST ( $n = 18$ , 62.1%), clinical progression ( $n = 1$ , 3.4%) or physician decision ( $n = 1$ , 3.4%).

Baseline demographics are summarized in Table 1. The median age was 59 years (range: 33–87) and patients received a median of 2 (range: 1–8) prior systemic therapies. All 29 (100.0%) patients received prior 5-fluorouracil (5-FU) or capecitabine, 27 (93.1%) received oxaliplatin, 24 (82.8%) received irinotecan, 24 (82.8%) received bevacizumab and 5 (17.2%) received a prior KRAS G12C inhibitor as a single agent or as a combination therapy (2 patients had single-agent divarasisib, 1 had single-agent sotorasib, 1 had sotorasib with bevacizumab, and 1 had adagrasib with an inhibitor of Src homology region 2–containing protein tyrosine phosphatase-2 (SHP2)).

### Safety

The primary objective of this study was to evaluate the safety of divarasisib plus cetuximab. No dose-limiting toxicities were reported. All (100.0%) patients experienced at least one treatment-related adverse event (TRAE), with the majority of events being grade 1–2 (91.6%). The most common TRAEs included rash (96.6%; grouped term including dermatitis acneiform, rash, rash pustular, rash follicular and rash maculo-papular), diarrhea (82.8%), nausea (72.4%) and vomiting (48.3%). TRAEs occurring in ≥10% of patients are summarized in Table 2 and fully described in Extended Data Table 1. Grade 3 TRAEs occurred in 11 patients (37.9%) and included diarrhea ( $n = 3$ ), increased lipase

**Table 2 | TRAEs occurring in ≥10% of patients**

	TRAEs	Grade 3–4 <sup>b</sup> TRAEs
Total number of patients with at least one AE, n (%)	29 (100)	13 (44.8)
Rash <sup>a</sup>	28 (96.6)	2 (6.9)
Diarrhea	24 (82.8)	3 (10.3)
Nausea	21 (72.4)	0
Vomiting	14 (48.3)	0
Dry skin	10 (34.5)	1 (3.4)
Paronychia	6 (20.7)	1 (3.4)
Hypomagnesemia	4 (13.8)	2 (6.9)
Pruritus	4 (13.8)	1 (3.4)
Infusion-related reaction	4 (13.8)	1 (3.4)
Asthenia	4 (13.8)	0
Fatigue	4 (13.8)	0
Abdominal pain	3 (10.3)	1 (3.4)
Amylase increased	3 (10.3)	0
Pyrexia	3 (10.3)	0
Dysgeusia	3 (10.3)	0

<sup>a</sup>Rash grouped terms: dermatitis acneiform, rash, rash pustular, rash follicular and rash maculo-papular. <sup>b</sup>No grade 5 TRAEs reported.

( $n = 2$ ), rash ( $n = 2$ ) and abdominal pain, upper abdominal pain, dry skin, headache, hypomagnesemia, infusion-related reaction, insomnia, paronychia, pruritus and white blood cell count decrease ( $n = 1$  for each). Grade 4 TRAEs occurred in 2 patients (6.9%) and included hypomagnesemia ( $n = 1$ ) and neutropenia ( $n = 1$ ). No grade 5 TRAEs occurred. Serious adverse events (AEs) occurred in 7 patients (24.1%), with none related to study treatment. Three deaths due to CRC progression occurred during safety follow-up.

TRAEs led to divarasil dose modifications (interruption, reduction or withdrawal) in 10 patients (34.5%), with divarasil dose interruptions in 7 patients (24.1%), divarasil dose reductions in 4 patients (13.8%) and no divarasil treatment withdrawals. TRAEs that led to divarasil dose reduction included diarrhea in 3 patients (10.3%, all grade 3) and vomiting in 1 patient (3.4%, grade 1). TRAEs led to cetuximab dose modifications (interruption, reduction or withdrawal) in 11 patients (37.9%), with cetuximab dose interruptions in 9 patients (31.0%), cetuximab dose reductions in 4 patients (13.8%) and cetuximab withdrawal in 1 patient (3.4%). TRAEs that led to cetuximab dose reduction include infusion-related reactions in 2 patients (6.9%, one grade 2 and one grade 1), and dermatitis acneiform, paronychia and pustular rash in 1 patient each (3.4%, grade 2 pustular rash, grade 2 paronychia and grade 3 dermatitis acneiform). Treatment-related grade 3 rash led to cetuximab withdrawal in 1 patient who continued to receive divarasil.

### Antitumor activity

A secondary objective of this study was to assess the preliminary antitumor activity of divarasil plus cetuximab. Antitumor activity was determined by the investigator according to RECIST v1.1 (see the study end points in the Methods for further definitions), and all 29 patients had measurable disease at baseline (Fig. 2). Of the 24 patients who had not previously received a KRAS G12C inhibitor before enrollment, 1 patient received divarasil at 200 mg in combination with cetuximab and 23 patients received divarasil at 400 mg in combination with cetuximab. Among the 24 patients, 1 patient (4.2%; 1/1 confirmed) had a complete response (CR), 15 (62.5%; 14/15 confirmed) had a partial response (PR), and 8 (33.3%) had stable disease (SD) as their best response, for a confirmed ORR of 62.5% (95% confidence interval (CI): 40.6%, 81.2%). As an

ad hoc end point, the median time to response was 1.4 months (range: 1.2–9.8). The median duration of response was 6.9 months (95% CI: 5.6, not estimable; Fig. 3). The median PFS was 8.1 months (95% CI: 5.5, 12.3). One patient experienced a 33.3% increase from baseline in the target lesion sum of diameters, but was assessed with a best response of SD based on the investigator's interpretation of RECIST v1.1 in light of the response observed in the non-target lesions. Among the 5 patients who had received KRAS G12C inhibitors before enrollment, 3 (60.0%; 3/3 confirmed) had a PR and 2 (40.0%) had SD as their best response.

### Pharmacokinetics

Another secondary objective in this study was to characterize the pharmacokinetic profile of divarasil plus cetuximab. We previously reported that the mean half-life of a single dose of divarasil 400 mg administered as a single agent was  $17.6 \pm 2.7$  h and the corresponding accumulation index after daily dosing to steady state (area under the concentration–time curve from 0 to 24 h ( $R_{AUC0-24}$ )) was  $1.4 \pm 0.4$  (ref. 11). The steady-state pharmacokinetic profile and  $R_{AUC0-24}$  of divarasil (400 mg once daily) in combination with cetuximab were similar to single-agent divarasil (Extended Data Table 2 and Extended Data Fig. 1).

### Biomarker analysis


Circulating tumor DNA (ctDNA) is an emerging biomarker for monitoring treatment effect, tracking tumor evolution and identifying potential mechanisms of resistance to treatment. As an exploratory objective in this study, retrospective ctDNA profiling was conducted with longitudinal plasma samples collected at baseline (CID1), on-treatment (multiple time points) and end-of-treatment (EoT) visits.

KRAS G12C variant allele frequency (VAF) from circulating cell-free DNA (cfDNA) was monitored at baseline (CID1) and at early on-treatment time points (cycle 1 day 15 (CID15) and cycle 3 day 1 (C3D1)). At CID1, the KRAS G12C mutation was detected from cfDNA in 22 of 25 patients evaluated. Decline in KRAS G12C VAF as early as CID15 was observed in patients who had a response or SD. At C3D1, the VAF of KRAS G12C was  $<0.5\%$  in 17 of these 22 patients (77.3%) including patients with a response or SD (Fig. 4a).

To explore the mechanisms of potential acquired resistance, we conducted ctDNA profiling from paired baseline and disease progression/EoT plasma samples. Of the 14 patients profiled, 13 patients (92.9%) had at least one acquired genomic alteration that may be associated with treatment resistance at EoT. Ten patients had at least one alteration in the KRAS gene (excluding the G12C mutation), including copy number gain/amplification, non-G12C pathogenic mutations that can result in oncogenic activation of KRAS, and secondary mutations that may diminish the binding of divarasil to the KRAS G12C protein. Other acquired genomic alterations observed at EoT include alterations in NRAS/HRAS (observed in 4/14 patients), genes in the MAPK pathway (8/14 patients), PI3K pathway (4/14 patients), RTK pathway (8/14 patients) and others (for example, MYC copy number gain; 2/14 patients; Fig. 4b).

### Discussion

The KRAS G12C mutation is associated with worse overall survival in patients with CRC and is readily identified through standard-of-care testing, thus highlighting an area of need for more effective and targeted therapeutic approaches<sup>4</sup>. Current first-line standard of care for KRAS G12C-positive CRC includes 5-FU-based chemotherapy with irinotecan, oxaliplatin and/or capecitabine, but is limited by low tumor-specific selectivity and systemic toxicity<sup>21</sup>. Several KRAS G12C inhibitors, including divarasil, sotorasil and adagrasil, are currently being investigated as a single agent and in combination with EGFR inhibitors to target this unmet need, although they vary in their safety, antitumor activity and clinical benefit profiles.




**Fig. 2 | Antitumor activity for all patients.** **a**, Waterfall plot showing the best percentage decrease from baseline in the tumor burden (defined as the sum of the longest diameters of all target lesions) in all 29 patients. **b**, Swimmer plot

showing the time on study treatment, best response, and reason for treatment discontinuation for all 29 patients. **c**, Spider plot of the percentage changes from baseline in sum of tumor diameters over time in all 29 patients.

The combination of divarasin and cetuximab appeared to be well tolerated, and AEs were manageable with supportive medications and dose modifications. The most common AEs observed in this study were low-grade gastrointestinal AEs and rash, which were consistent with single-agent divarasin and cetuximab safety profiles, respectively<sup>11,22</sup>. No patients withdrew divarasin treatment due to TRAEs and only 1 patient (3.4%) withdrew from cetuximab treatment due to a TRAE. Furthermore, there was a low rate of divarasin dose reductions (13.8%), with interruptions in 24.1% of patients. Among patients treated with adagrasib plus cetuximab in KRYSTAL-1 ( $n = 32$ ), no patients discontinued adagrasib and 5 patients (16%) discontinued cetuximab due to

TRAEs, with adagrasib dose reductions reported in 10 patients (31%)<sup>20</sup>. In the CodeBreak300 study, TRAEs led to treatment discontinuation in 3.8% of patients in the 960 mg sotorasib plus panitumumab arm and 1.9% in the 240-mg sotorasib plus panitumumab arm<sup>17</sup>.

The improved antitumor activity observed with divarasin plus cetuximab in this study compared with single-agent divarasin is consistent with the hypothesis of EGFR-mediated adaptive feedback reactivation of the RAS–MAPK pathway following KRAS G12C inhibition. In patients with CRC who had not received prior KRAS G12C inhibitor treatment, single-agent divarasin achieved a response rate of 35.9%<sup>11</sup>, while the combination of divarasin and cetuximab achieved a response rate of 62.5%.




**Fig. 3 | Duration of response and PFS for KRAS G12C inhibitor-naive patients. a,** Kaplan–Meier plot for duration of response for the 16 KRAS G12C inhibitor-naive patients who experienced a CR or PR. **b,** Kaplan–Meier plot for median PFS for all 24 KRAS G12C inhibitor-naive patients.

Although cross-trial comparisons are difficult due to differences in patient populations, the ORR reported in this trial is numerically higher compared to that reported with 960 mg sotorasib plus panitumumab (26.4%) and adagrasib plus cetuximab (46%), as well as single-agent treatment of patients with CRC (35.9% for divarasib, 9.7% for sotorasib and 19% for adagrasib)<sup>16,17,20</sup>. Similarly, the median PFS of 8.1 months with divarasib observed in this trial is the longest reported for a KRAS G12C inhibitor combined with an EGFR inhibitor in patients with CRC (5.6 months (95% CI: 4.2, 6.3) with sotorasib plus panitumumab and 6.9 months (95% CI: 5.4, 8.1) for adagrasib plus cetuximab)<sup>17,20</sup>. Although preliminary evidence with the divarasib plus cetuximab combination is encouraging, this study was limited by the small number of patients enrolled into this arm and the lack of comparison of this divarasib and cetuximab combination to a standard-of-care treatment in *KRAS G12C*-positive CRC.

Divarasib has been shown to be 5 to 20 times more potent in vitro as compared to sotorasib and adagrasib<sup>10</sup>. This difference in potency may explain the numerically higher ORRs and longer PFS with divarasib

compared to sotorasib and adagrasib, as a single-agent and in combination with an EGFR inhibitor in patients with CRC. This is further supported by a numerically higher ORR seen with divarasib in patients with non-small cell lung cancer (56.4%) compared with sotorasib (37% in a phase 2 trial and 28% in a phase 3 trial) and adagrasib (43% in a phase 2 trial)<sup>11,23–25</sup>. This current trial also included 5 patients who previously received a KRAS G12C inhibitor, with a PR observed in 3 of the 5 patients (60.0%) when treated with divarasib plus cetuximab. In contrast, patients who previously received single-agent adagrasib therapy showed no additional responses when subsequently treated with adagrasib plus cetuximab combination therapy<sup>20</sup>.

Divarasib plus cetuximab treatment led to a decrease in *KRAS G12C* ctDNA levels. Of note, divarasib plus cetuximab combination therapy showed a larger decline in *KRAS G12C* ctDNA levels compared to single-agent divarasib (77.3% versus 45.7% of patients with detectable *KRAS G12C* ctDNA at C1D1 had *KRAS G12C* VAF decline to below 0.5% at C3D1)<sup>11</sup>. Upon disease progression with divarasib plus cetuximab,



**Fig. 4 | Biomarker analysis of ctDNA. a**, Shown is the *KRAS G12C* VAF at baseline (C1D1) and early treatment time points (C1D15, C3D1) among patients with a detectable *KRAS G12C* mutation from cfDNA at C1D1 ( $n = 20$  shown, each line represents one patient). Two patients with missing C1D15 plasma samples are not shown in the plot. Box-and-whisker plots at each time point in each indication show the median (center line) with the minima and maxima box boundaries representing the 25th and 75th percentiles; whiskers represent the minimum

and maximum values of the data that are within 1.5 times the interquartile range under the 25th and over the 75th percentiles. **b**, Shown are putative genetic mechanisms of acquired resistance to divarasinib plus cetuximab combination treatment among 14 patients who had an EoT visit before 01 May 2023. Each row represents one patient with the first four columns describing assigned divarasinib dose, best response, PFS, prior *KRAS G12C* inhibitor use and subsequent columns indicating acquired genomic alterations at EoT.

the majority (92.9%) of patients profiled had at least one genomic alteration that may be associated with treatment resistance similarly to two previous reports<sup>26,27</sup>, which is higher than that of patients treated with divarasinib (30.2%) or other *KRAS G12C* inhibitors as single agent<sup>11,28,29</sup>. This observation may be due to a more potent treatment effect with the combination of divarasinib and cetuximab imposing a stronger selective pressure and/or potentially increasing the adaptive mutability of the residual cancer cells<sup>30</sup>.

In conclusion, divarasinib in combination with cetuximab demonstrated a manageable safety profile and promising clinical activity. The further improvements in antitumor activity demonstrated with the addition of cetuximab to divarasinib may represent an effective strategy for overcoming resistance to *KRAS G12C* inhibitors. Divarasinib is continuing to be investigated with other anticancer therapies for patients with CRC in this study, including bevacizumab, GDC-1971 (a SHP2 inhibitor) and inavolisib (a PI3K $\alpha$  inhibitor). Additionally, a study is ongoing to explore the effects of the combination of divarasinib plus

cetuximab with or without chemotherapy (FOLFOX: 5-FU, leucovorin and oxaliplatin; or FOLFIRI: leucovorin, 5-FU and irinotecan; ClinicalTrials.gov: [NCT04929223](https://clinicaltrials.gov/ct2/show/study/NCT04929223)) in patients with *KRAS G12C*-positive CRC.

### Online content

Any methods, additional references, Nature Portfolio reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at <https://doi.org/10.1038/s41591-023-02696-8>.

### References

1. Khan, A. Q. et al. RAS-mediated oncogenic signaling pathways in human malignancies. *Semin. Cancer Biol.* **54**, 1–13 (2019).
2. Moore, A. R., Rosenberg, S. C., McCormick, F. & Malek, S. RAS-targeted therapies: is the undruggable drugged? *Nat. Rev. Drug Discov.* **19**, 533–552 (2020).

3. Henry, J. T. et al. Comprehensive clinical and molecular characterization of *KRAS*<sup>G12C</sup>-mutant colorectal cancer. *JCO Precis. Oncol.* **5**, PO.20.00256 (2021).
4. Jones, R. P. et al. Specific mutations in *KRAS* codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer. *Br. J. Cancer* **116**, 923–929 (2017).
5. Lee, J. K. et al. Comprehensive pan-cancer genomic landscape of *KRAS* altered cancers and real-world outcomes in solid tumors. *NPJ Precis. Oncol.* **6**, 91 (2022).
6. Nassar, A. H., Adib, E. & Kwiatkowski, D. J. Distribution of *KRAS*<sup>G12C</sup> somatic mutations across race, sex, and cancer type. *N. Engl. J. Med.* **384**, 185–187 (2021).
7. Schirripa, M. et al. *KRAS* G12C metastatic colorectal cancer: specific features of a new emerging target population. *Clin. Colorectal Cancer* **19**, 219–225 (2020).
8. Allegra, C. J. et al. American Society of Clinical Oncology provisional clinical opinion: testing for *KRAS* gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. *J. Clin. Oncol.* **27**, 2091–2096 (2009).
9. Van Cutsem, E. et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. *Ann. Oncol.* **27**, 1386–1422 (2016).
10. Purkey, H. Discovery of GDC-6036, a clinical stage treatment for *KRAS* G12C-positive cancers. in *AACR Annual Meeting* (New Orleans, 2022).
11. Sacher, A. et al. Single-agent divarasis (GDC-6036) in solid tumors with a *KRAS* G12C mutation. *N. Engl. J. Med.* **389**, 710–721 (2023).
12. Amodio, V. et al. EGFR blockade reverts resistance to *KRAS*<sup>G12C</sup> inhibition in colorectal cancer. *Cancer Discov.* **10**, 1129–1139 (2020).
13. Ryan, M. B. et al. *KRAS*<sup>G12C</sup>-independent feedback activation of wild-type RAS constrains *KRAS*<sup>G12C</sup> inhibitor efficacy. *Cell Rep.* **39**, 110993 (2022).
14. Ryan, M. B. et al. Vertical pathway inhibition overcomes adaptive feedback resistance to *KRAS*<sup>G12C</sup> inhibition. *Clin. Cancer Res.* **26**, 1633–1643 (2020).
15. Lito, P., Solomon, M., Li, L. S., Hansen, R. & Rosen, N. Allele-specific inhibitors inactivate mutant *KRAS* G12C by a trapping mechanism. *Science* **351**, 604–608 (2016).
16. Fakih, M. G. et al. Sotorasib for previously treated colorectal cancers with *KRAS*<sup>G12C</sup> mutation (CodeBreak100): a prespecified analysis of a single-arm, phase 2 trial. *Lancet Oncol.* **23**, 115–124 (2022).
17. Fakih, M. G. et al. Sotorasib plus panitumumab in refractory colorectal cancer with mutated *KRAS* G12C. *N. Engl. J. Med.* <https://doi.org/10.1056/NEJMoa2308795> (2023).
18. Hong, D. S. et al. *KRAS*<sup>G12C</sup> inhibition with sotorasib in advanced solid tumors. *N. Engl. J. Med.* **383**, 1207–1217 (2020).
19. Ou, S. I. et al. First-in-human phase I/II dose-finding study of adagrasib (MRTX849) in patients with advanced *KRAS*<sup>G12C</sup> solid tumors (KRYSTAL-1). *J. Clin. Oncol.* **40**, 2530–2538 (2022).
20. Yaeger, R. et al. Adagrasib with or without cetuximab in colorectal cancer with mutated *KRAS* G12C. *N. Engl. J. Med.* **388**, 44–54 (2023).
21. Xie, Y. H., Chen, Y. X. & Fang, J. Y. Comprehensive review of targeted therapy for colorectal cancer. *Signal Transduct. Target Ther.* **5**, 22 (2020).
22. ERBITUX (cetuximab) [package insert]. Branchburg, NJ: ImClone (2004). Accessed 08 Nov 2023.
23. de Langen, A. J. et al. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with *KRAS*<sup>G12C</sup> mutation: a randomised, open-label, phase 3 trial. *Lancet* **401**, 733–746 (2023).
24. Janne, P. A. et al. Adagrasib in non-small-cell lung cancer harboring a *KRAS*<sup>G12C</sup> mutation. *N. Engl. J. Med.* **387**, 120–131 (2022).
25. Skoulidis, F. et al. Sotorasib for lung cancers with *KRAS* p.G12C mutation. *N. Engl. J. Med.* **384**, 2371–2381 (2021).
26. Yaeger, R. et al. Molecular characterization of acquired resistance to *KRAS*<sup>G12C</sup>-EGFR inhibition in colorectal cancer. *Cancer Discov.* **13**, 41–55 (2023).
27. Hong, D. S. et al. Abstract 2308: Biomarkers of acquired resistance to sotorasib (soto) plus panitumumab (pani) in chemorefractory *KRAS* G12C-mutated metastatic colorectal cancer (mCRC). *Cancer Res.* **83**, 2308 (2023).
28. Awad, M. M. et al. Acquired resistance to *KRAS*<sup>G12C</sup> inhibition in cancer. *N. Engl. J. Med.* **384**, 2382–2393 (2021).
29. Li, B. T. et al. Largest evaluation of acquired resistance to sotorasib in *KRAS* p.G12C-mutated non-small cell lung cancer (NSCLC) and colorectal cancer (CRC): plasma biomarker analysis of CodeBreak100. *J. Clin. Oncol.* **40**, 102 (2022).
30. Russo, M. et al. Adaptive mutability of colorectal cancers in response to targeted therapies. *Science* **366**, 1473–1480 (2019).

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© Crown 2023

Jayesh Desai<sup>1</sup>✉, Guzman Alonso<sup>2</sup>, Se Hyun Kim<sup>3</sup>, Andres Cervantes<sup>4</sup>, Thomas Karasic<sup>5</sup>, Laura Medina<sup>6</sup>, Einat Shacham-Shmueli<sup>7</sup>, Rasha Cosman<sup>8</sup>, Alejandro Falcon<sup>9</sup>, Eelke Gort<sup>10</sup>, Tormod Guren<sup>11</sup>, Erminia Massarelli<sup>12</sup>, Wilson H. Miller Jr.<sup>13</sup>, Luis Paz-Ares<sup>14</sup>, Hans Prenen<sup>15</sup>, Alessio Amatu<sup>16</sup>, Chiara Cremolini<sup>17</sup>, Tae Won Kim<sup>18</sup>, Victor Moreno<sup>19</sup>, Sai-Hong I. Ou<sup>20</sup>, Alessandro Passardi<sup>21</sup>, Adrian Sacher<sup>22</sup>, Armando Santoro<sup>23</sup>, Rafal Stec<sup>24,25</sup>, Susanna Ulahannan<sup>26,27</sup>, Kathryn Arbour<sup>28</sup>, Patricia Lorusso<sup>29</sup>, Jia Luo<sup>30</sup>, Manish R. Patel<sup>31</sup>, Yoonha Choi<sup>32</sup>, Zhen Shi<sup>32</sup>, Sandhya Mandlekar<sup>32</sup>, Mark T. Lin<sup>32</sup>, Stephanie Royer-Joo<sup>32</sup>, Julie Chang<sup>32</sup>, Tomi Jun<sup>32</sup>, Neekesh V. Dharia<sup>32</sup>, Jennifer L. Schutzman<sup>32</sup>, GO42144 Investigator and Study Group\* & Sae-Won Han<sup>33</sup>✉

<sup>1</sup>Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia. <sup>2</sup>Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Barcelona, Spain. <sup>3</sup>Seoul National University Bundang Hospital, Seongnam, South Korea. <sup>4</sup>Hospital Clinico Universitario De Valencia, Valencia, Spain. <sup>5</sup>Abramson Cancer Center, University Of Pennsylvania, Philadelphia, PA, USA. <sup>6</sup>Medical Oncology Intercenter Unit, Regional and Virgen de la Victoria University Hospitals, IBIMA, Málaga, Spain. <sup>7</sup>Sheba Medical Center, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. <sup>8</sup>The Kinghorn Cancer Centre, St. Vincent's Hospital and School of Medicine, University of New South Wales, Sydney, Australia. <sup>9</sup>Hospital Universitario Virgen del Rocío, Sevilla, Spain. <sup>10</sup>Universitair Medisch Centrum Utrecht, Utrecht, Netherlands. <sup>11</sup>Oslo University Hospital Radiumhospitalet, Oslo, Norway. <sup>12</sup>City of Hope - Comprehensive Cancer Center, Duarte, CA, USA. <sup>13</sup>Lady Davis Institute and Segal Cancer Center, Jewish General Hospital, McGill University, Montreal, Quebec, Canada. <sup>14</sup>Hospital Universitario 12 de Octubre, H120-CNIO Lung Cancer Unit, Universidad Complutense and Ciberonc, Madrid, Spain. <sup>15</sup>University Hospital Antwerp, Edegem, Belgium. <sup>16</sup>Haematology and Oncology Division, Grande Ospedale Metropolitano Niguarda, Milan, Italy. <sup>17</sup>University of Pisa, Pisa, Italy. <sup>18</sup>Department of Oncology, Asan Medical Center, University of Ulsan, Seoul, South Korea. <sup>19</sup>START MADRID-FJD, Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain. <sup>20</sup>University of California Irvine School of Medicine, Chao Family Comprehensive Cancer Center, Orange, CA, USA. <sup>21</sup>Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy. <sup>22</sup>Princess Margaret Cancer Centre, University Health Network, Toronto, Canada, Department of Medicine & Department of Immunology, University of Toronto, Toronto, Ontario, Canada. <sup>23</sup>Humanitas University and IRCCS Humanitas Research Hospital-Humanitas Cancer Center, Milan, Italy. <sup>24</sup>Biokinetica, Przychodnia Jozefow, Józefów, Poland. <sup>25</sup>Warsaw Medical University, Warsaw, Poland. <sup>26</sup>Stephenson Cancer Center, Oklahoma City, OK, USA. <sup>27</sup>Sarah Cannon Research Institute, Nashville, TN, USA. <sup>28</sup>Memorial Sloan Kettering Cancer Center, New York City, NY, USA. <sup>29</sup>Yale Cancer Center, Yale University, New Haven, CT, USA. <sup>30</sup>Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. <sup>31</sup>Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL, USA. <sup>32</sup>Genentech, South San Francisco, CA, USA. <sup>33</sup>Seoul National University Hospital and Seoul National University Cancer Research Institute, Seoul, South Korea. \*A list of authors and their affiliations appears at the end of the paper.

✉ e-mail: [jayesh.desai@petermac.org](mailto:jayesh.desai@petermac.org); [saewon1@snu.ac.kr](mailto:saewon1@snu.ac.kr)

### GO42144 Investigator and Study Group

**Jayesh Desai<sup>1</sup>, Guzman Alonso<sup>2</sup>, Se Hyun Kim<sup>3</sup>, Andres Cervantes<sup>4</sup>, Thomas Karasic<sup>5</sup>, Laura Medina<sup>6</sup>, Einat Shacham-Shmueli<sup>7</sup>, Rasha Cosman<sup>8</sup>, Alejandro Falcon<sup>9</sup>, Eelke Gort<sup>10</sup>, Tormod Guren<sup>11</sup>, Erminia Massarelli<sup>12</sup>, Wilson H. Miller Jr.<sup>13</sup>, Luis Paz-Ares<sup>14</sup>, Hans Prenen<sup>15</sup>, Alessio Amatu<sup>16</sup>, Chiara Cremolini<sup>17</sup>, Tae Won Kim<sup>18</sup>, Victor Moreno<sup>19</sup>, Sai-Hong I. Ou<sup>20</sup>, Alessandro Passardi<sup>21</sup>, Adrian Sacher<sup>22</sup>, Armando Santoro<sup>23</sup>, Rafal Stec<sup>24,25</sup>, Susanna Ulahannan<sup>26,27</sup>, Kathryn Arbour<sup>28</sup>, Patricia Lorusso<sup>29</sup>, Jia Luo<sup>30</sup>, Manish R. Patel<sup>31</sup>, Yoonha Choi<sup>32</sup>, Zhen Shi<sup>32</sup>, Sandhya Mandlekar<sup>32</sup>, Mark T. Lin<sup>32</sup>, Stephanie Royer-Joo<sup>32</sup>, Julie Chang<sup>32</sup>, Tomi Jun<sup>32</sup>, Neekesh V. Dharia<sup>32</sup>, Jennifer L. Schutzman<sup>32</sup> & Sae-Won Han<sup>33</sup>**

A full list of members and their affiliations appears in the Supplementary Information.



## Methods

### Study design

Divarasis plus cetuximab combination data are reported from arm C of an ongoing phase 1b, open-label, multicenter, dose-escalation and dose-expansion study of divarasis in combination with other anticancer therapies in patients with advanced or metastatic solid tumors that harbor a *KRAS G12C* mutation (NCT04449874).

Patients received oral divarasis 200 or 400 mg once daily and intravenous cetuximab (400 mg/m<sup>2</sup> on C1D1, then 250 mg/m<sup>2</sup> once weekly) in 21-d cycles until intolerable toxicity, disease progression or patient withdrawal. Patients were enrolled in a 3 + 3 dose-escalation design at 200 mg and 400 mg divarasis, then enrolled into dose-expansion cohorts of 400 mg divarasis. As described in the protocol, an Internal Monitoring Committee was involved to ensure that appropriate patient safety oversight is maintained throughout the conduct of this study. The redacted protocol is available in the Supplementary Information.

This study was conducted in full conformance with the ICH E6 guideline for Good Clinical Practice and the Declaration of Helsinki, or the applicable laws and regulations of the country in which the research is conducted, whichever affords the greater protection to the individual. The protocol was approved by the institutional review boards at City of Hope Comprehensive Cancer Center, Princess Margaret Cancer Center, Peter MacCallum Cancer Center, Jewish General Hospital, Universitair Medisch Centrum Utrecht, Biokinetica Przychodnia Jozefow, Istituto Scientifico Romagnolo per lo Studio y la Cura dei Tumori, Asst Grande Ospedale Metropolitano Niguarda, UZ Antwerpen, Hospital Universitario Virgen Del Rocio, Hospital Universitari Vall D'hebron, Seoul National University Hospital, Seoul National University Bundang Hospital, Hospital Clinico Universitario De Valencia, Hospital Universitario 12 De Octubre, Sheba Medical Center and Abramson Cancer Center. Patients provided signed informed consent before enrollment.

### Patients

Patients 18 years or older with locally advanced, recurrent or metastatic incurable adenocarcinoma of the colon or rectum harboring a *KRAS G12C* mutation documented by either central testing of blood samples (FoundationOne Liquid CDx/F1LCDx) or local testing of tumor tissue or blood samples (using a validated molecular testing method) were enrolled from 17 sites in 10 countries.

Patients were included based on the following inclusion criteria: disease that had progressed after at least one available standard therapy, or for which standard therapy has shown to be ineffective or intolerable, or for which a clinical trial of an investigational agent is a recognized standard of care; evaluable or measurable disease per RECIST v1.1; Eastern Cooperative Oncology Group performance status of 1 or lower (a five-point scale where higher numbers reflect greater disability); life expectancy  $\geq 12$  weeks; adequate hematologic and organ function within 14 d before initiation of study treatment defined as absolute neutrophil count  $\geq 1,200/\mu\text{l}$ , hemoglobin  $\geq 9 \text{ g dl}^{-1}$ , platelet count  $\geq 100,000/\mu\text{l}$ , total bilirubin  $\leq 1.5$  times the upper limit of normal (ULN), serum albumin  $\geq 2.5 \text{ g dl}^{-1}$ , aspartate transaminase (AST) and alanine transaminase (ALT)  $\leq 2.5$  times ULN (patients with documented liver metastases may have AST and ALT  $\leq 5.0$  times the ULN), serum creatinine  $\leq 1.5$  times the ULN or creatinine clearance  $\geq 50 \text{ ml min}^{-1}$  based on the Cockcroft–Gault estimation, and an international normalized ratio and activated partial thromboplastin time  $< 1.5$  times the ULN (for those not receiving therapeutic anticoagulation); for women of childbearing potential to be abstinent or use contraception, and refrain from donating eggs/sperm for at least 6 months after divarasis and 2 months after cetuximab treatment; for nonsurgically sterile men to be abstinent or use contraception, and refrain from donating sperm for at least 4 months after divarasis and 2 months after cetuximab treatment; not have a known concomitant second oncogenic driver (for example, *BRAF*<sup>V600E</sup> mutation, *ERBB2* amplification) as determined by Foundation Medicine; NGS assay or local testing of tumor tissue or

blood samples (using a validated molecular testing method); and for patients required to provide pre-treatment and on-treatment biopsy samples, accessible lesion(s) that permit a total of at least two biopsy samples (pre-treatment and on-treatment) without unacceptable risk of a procedural complication. Patients with prior *KRAS G12C* inhibitor treatment must not have discontinued due to toxicity related to the prior *KRAS G12C* inhibitor and were required to provide tumor tissue specimens collected before and after treatment with the prior *KRAS G12C* inhibitor.

Patients were excluded based on the following criteria: inability/unwillingness to swallow pills; inability/unwillingness to comply with study or follow-up procedures; malabsorption syndrome or other condition that would interfere with enteral absorption; active, untreated CNS metastases (previously treated CNS metastases were allowed if they had measurable or evaluable disease outside the CNS, no history of intracranial or spinal cord hemorrhage, no ongoing requirement for corticosteroids for CNS metastases (with corticosteroids discontinued for  $\geq 2$  weeks before enrollment and no ongoing symptoms attributed to CNS metastases), no stereotactic radiation within 7 d or whole-brain radiation within 14 d before C1D1, and no evidence of interim progression between completion of CNS-directed therapy and screening radiographic study); leptomeningeal disease or carcinomatous meningitis; uncontrolled pleural effusion, pericardial effusion or ascites requiring recurrent drainage procedures biweekly or more frequently; any active infection that could impact patient safety or serious infection requiring intravenous antibiotics within 7 d before C1D1; clinical history of liver disease, including viral or other hepatitis, current alcohol abuse or cirrhosis; known HIV infection; any other diseases, active or uncontrolled pulmonary dysfunction, metabolic dysfunction, physical examination finding or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug, that may affect the interpretation of the results, or renders the patients at high risk from treatment complications; uncontrolled hypercalcemia ( $>1.5 \text{ mmol}^{-1}$  ionized calcium or  $12 \text{ mg dl}^{-1}$  calcium or  $\geq$  corrected serum calcium ULN) or symptomatic hypercalcemia requiring continued use of bisphosphonate therapy or denosumab; traumatic injury or major surgical procedure within 4 weeks before C1D1; patients with chronic diarrhea, short bowel syndrome or upper gastrointestinal surgery including gastric resection, a history of inflammatory bowel disease or any active bowel inflammation (including diverticulitis); treatment with another anticancer therapy within 3 weeks or five half-lives before initiation of study treatment, whichever is shorter, or endocrine therapy within 2 weeks before initiation of study treatment, except for hormonal therapy with gonadotropin-releasing hormone agonists or antagonists for endocrine-sensitive cancers (approved kinase inhibitors may be used up to 2 weeks before initiation of study treatment, provided any drug-related toxicity has completely resolved); radiation therapy as cancer therapy within 4 weeks before initiation of study treatment; palliative radiation to bony metastases within 2 weeks before initiation of divarasis; AEs from prior anticancer therapy that have not resolved to grade 1 except for alopecia, vitiligo, endocrinopathy managed with replacement therapy or grade 2 peripheral neuropathy; history of other malignancy within 5 years before screening, with the exception of patients with a negligible risk of metastasis or death and/or treated with expected curative outcome; history of or active cardiovascular dysfunction, including history of stroke or transient ischemic attack within 6 months before first dose of study treatment, history of myocardial infarction within 6 months before first dose of study treatment, New York Heart Association Class III or IV cardiac disease or congestive heart failure requiring medication, uncontrolled arrhythmias, history of or active ventricular arrhythmia requiring medication, coronary heart disease that is symptomatic or unstable angina, congenital long QT syndrome or QT interval corrected through use of Fridericia's formula  $>470 \text{ ms}$  demonstrated by at least two electrocardiograms

30 min apart, or family history of sudden unexplained death or long QT syndrome, current treatment with medications that are well known to prolong the QT interval; pregnant or breastfeeding, or intending to become pregnant during the study or within 6 months after the final dose of divarasib (women of childbearing potential (including those who have had a tubal ligation) must have a negative serum pregnancy test result within 14 d before initiation of study drug); presence of appendiceal tumor; known hypersensitivity to study treatments; and history of idiopathic pulmonary fibrosis, organizing pneumonia (for example, bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography scan (history of radiation pneumonitis in the radiation field (fibrosis) was permitted).

### Study assessments

Safety was assessed through the evaluation of AEs (NCI CTCAE v5.0), changes in laboratory test results and changes in vital signs and electrocardiograms, and included all patients who received at least one dose of both study drugs. Attribution of AEs to study drug was determined by the investigator. For each AE requiring a dose modification, only one action taken with study drug was selected according to the following hierarchy: withdrawal, reduction and interruption. Preliminary antitumor activity was determined by the investigator according to RECIST v1.1. Confirmed ORR was defined as the proportion of patients with measurable disease at baseline with CR or PR on two consecutive tumor assessments at least 4 weeks apart, while the best response did not require a confirmatory assessment. PFS was defined as the time from first treatment to the first occurrence of disease progression or death from any cause during the study (whichever occurred first).

### Pharmacokinetics

Pharmacokinetic parameters were estimated using non-compartmental analysis of concentration–time data. Plasma samples were evaluated for divarasib using a validated liquid chromatography tandem mass spectrometry assay. The lower and upper limit of quantification for divarasib was 5 ng ml<sup>-1</sup> and 5,000 ng ml<sup>-1</sup>, respectively. A stable labeled internal standard was used. Pharmacokinetic non-compartmental analysis was performed with nominal time using Phoenix WinNonlin (Certara USA, version 8.3). Graphical visualization was done using R (version 4.2.0; R Foundation for Statistical Computing). Pharmacokinetic samples at steady state were collected before dose, and at 0.5, 1, 2, 3, 4 and 8 h after dose on cycle 1 day 8 (C1D8) or on cycle 2 day 1 (C2D1). C1D8 or C2D1 AUC<sub>0–24</sub> calculations included imputation of the 24-h time point based on pre-dose C1D8 or C2D1 plasma concentration of divarasib.

### Statistical analysis

The study planned to enroll approximately 29 patients in the cetuximab combination cohorts. This study was intended to obtain preliminary safety, pharmacokinetic and antitumor activity information and the sample sizes do not reflect any power and type I considerations. The data cutoff date was 01 April 2023 with an enrollment cutoff of 07 October 2022. This analysis included all patients who received at least one dose of divarasib and cetuximab. The response rate was reported for patients with measurable disease at baseline and summarized with 95% CIs calculated using the Clopper–Pearson method. The time-to-event end points, including time to response, duration of response and PFS, were reported descriptively and were summarized using the Kaplan–Meier method; median estimates were reported with 95% CIs.

### Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

### Data availability

*KRAS G12C* VAF data are available in the Supplementary Information. For eligible studies, qualified researchers may request access to individual patient-level clinical data through a data request platform. At the time of writing, this request platform is Vivli (<https://vivli.org/ourmember/roche/>). As this study is ongoing, access to patient-level data from this trial will not be available until at least 18 months after the last patient visit and a clinical study report has been completed. After that time, requests for data will be assessed by an independent review panel, which decides whether the data will be provided. On average, it takes a few months to access data in the Vivli platform, but the timeline will vary depending on the number of data contributors, the number of studies and your availability to respond to comments. Once approved, the data are available for up to 24 months.

For up-to-date details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see <https://www.roche.com/innovation/process/clinical-trials/data-sharing/>. Anonymized records for individual patients across more than one data source external to Roche cannot, and should not, be linked due to a potential increase in risk of patient reidentification.

### Acknowledgements

This study was sponsored by Genentech. We thank the patients and family members that were involved in this trial, as well as the clinical study teams. Writing assistance was provided by A. Occiano and S. Diaz of Genentech.

### Author contributions

All authors participated in study design and conduct, in data acquisition, analysis and interpretation and in drafting and revising the manuscript. Y.C. performed statistical analyses. S.M. verified the pharmacokinetic data. Z.S. verified the biomarker data. All authors approved the final version before submission.

### Competing interests

J.D. served as a consultant for BeiGene, Pierre Fabre, Bayer, GSK, Merck, Boehringer Ingelheim, Roche/Genentech, Daiichi Sankyo Europe, Novartis, Pfizer, Ellipses Pharma, Axelia Oncology and Amgen; and reports funding to their institution from Roche, GSK, Novartis, BeiGene, Lilly, Bristol Myers Squibb, AstraZeneca/MedImmune and Amgen. S.H.K. was a consultant on the advisory boards for Pfizer, Daiichi, Takeda and Astellas; and reports funding to their institution from Ono Pharma and Eisai Korea. A.C. received institutional research funding from Genentech, Merck Serono, Bristol Myers Squibb, Merck Sharp & Dohme, Roche, Beigene, Bayer, Servier, Lilly, Novartis, Takeda, Astellas, Natera and Fibrogen and advisory board or speaker fees from AbbVie, Amgen, Merck Serono, GlaxoSmithKline and Roche. T.K. has received honoraria from Incyte, Pfizer, Ipsen, AstraZeneca/MedImmune, Taiho Oncology, Elevar Therapeutics and Nucorion; and reports funding to their institution from Taiho Pharmaceutical, H3 Biomedicine, Bristol Myers Squibb, Lilly, Tempest Therapeutics, Xencor, Genentech, Incyte and Totus Medicines. L.M. has received travel and accommodation fees from Sevier, Novartis, Janssen, Bristol Myers Squibb; is on the speaker's bureau for Novartis; has received research funding from AstraZeneca; and reports funding to their institution from Bristol Myers Squibb, AstraZeneca, Abbvie, Genmab, Nelum, Numab and Precision Medicine. E.S. reports funding to their institution from Amgen, Bristol Myers Squibb, Daiichi Sankyo, Genentech, Lutris Pharma, MSD, Novartis and Pangea Pharma. R.C. reports funding to their institution from Abbvie, AkesoBio, AcrolImmune, ALX Oncology, Arcus, Ascendis Pharma, Amgen, ARIAD Pharmaceuticals, Array BioPharma, AstraZeneca, Bayer, Beigene, Biosplice Therapeutics, Bristol Myers Squibb, Blueprint Medicines Corporation, Boehringer, Boston Biomedical, BridgeBio, Carina Biotech, CBT Pharmaceuticals, Celgene, Corvus Pharmaceuticals,

GSK, CSTONE Pharmaceuticals, Daichii Sankyo, Duality, DynamiCure, ENB Therapeutics, EтираRX, Exelisis, Five Prime Therapeutics, Foghorn Therapeutics, Fortrea, Fusion Pharmaceuticals, GC Cell, Genentech, Gilead, Grey Wolf Therapeutics, Henlius, Biotech, ICON, IDEAYA Biosciences, Immunocore, Incyte, Innovent Biologics, InxMed, Janssen, Linnaeus Therapeutics, Lilly, Loxo, MacroGenics, Merck, Merrimack Pharmaceuticals, MSD, Moderna, Multitude Therapeutics, Myeloid Therapeutics, Nektar Therapeutics, Neoleukin Therapeutics, Novartis, NuvOx Pharma, Pfizer, QBiotech, Regeneron, Relay Therapeutics, Roche, Sanofi, Seagen, Starpharma, SERVIER AFFAIRES MÉDICALES, Takeda, TigerMed, ViroCure, Virogin Biotech, Xencore and Xennials Therapeutics. A.F. has received consultation fees from Seagen, Roche, Pfizer, Novartis, AstraZeneca, GSK and Esteve; and is on the speaker's bureau for Seagen, Roche, Pfizer, Novartis, Lilly, AstraZeneca, Pierre Fabre, Daiichi, Gilead and Eisai. T.G. reports honoraria to their institution from Pierre Fabre. W.H.M is on the advisory boards of and has received consulting fees from Merck, Bristol Myers Squibb, Roche, GSK, Novartis, Amgen, Mylan, EMD Serono and Sanofi; is on the speaker's bureau of and has received honoraria from Bristol Myers Squibb, Merck, Roche, GSK, Novartis, Amgen, Mylan, EMD Serono and Sanofi; reports grants paid to their institution from Merck, Canadian Institutes of Health Research, CRS, Terry Fox Research Institute, Samuel Waxman Cancer Research Foundation and Canadian Cancer Society Research Institute; and reports clinical trial support to their institution from Merck, MiMic, Astellas, Bristol Myers Squibb, Novartis, GSK, Incyte, Pfizer, Sanofi, Ocellaris Pharma, Alkermes, Genentech, Array, Exelisis, VelosBio, Esperas Pharma, Seagen, AstraZeneca and Roche. E.M. was an advisory board consultant for Lilly, Janssen Scientific Affairs, Bristol Myers Squibb, Daiichi Sankyo, AbbVie Consulting, Mirati Therapeutics, Fusion Pharmaceuticals, Iovance Biotherapeutics, Sanofi and Gilead; and was on the speaker's bureau for AstraZeneca, Lilly, Takeda Pharmaceuticals and Mirati Therapeutics. L.P. has received consulting fees from Lilly, MSD, Roche, PharmaMar, Merck KgaA (Darmstadt, Germany), AstraZeneca, Novartis, Servier, Amgen, Pfizer, Sanofi, Bayer, Bristol Myers Squibb, Mirati, GSK, Janssen, Takeda, Regeneron and Sanofi; grants or contracts from MSD, AstraZeneca, Bristol Myers Squibb and Pfizer; and is on the speaker's bureau and has received honoraria from AstraZeneca, Janssen, Merck, Mirati and Sanofi. H.P. has received honoraria from Amgen, Roche, Sanofi, AstraZeneca and Bayer. C.C. has received honoraria for speaker or advisory roles from Bayer, Roche, Merck Serono, Amgen, Servier, Mirati, Pierre Fabre, MSD, Nordic Pharma and Takeda; and research grants from Bayer, Servier, Merck and Amgen. T.W.K. reports funding to their institution from Genentech. V.M. has received consulting fees from Roche, Bayer, Bristol Myers Squibb, Janssen, Syneos, Affimed and AstraZeneca; and reports funding to their institution from Achilles, AbbVie, AceaBio, Adaptimmune, ADC Therapeutics, Arcus, Ascendis Pharma, Aduro, Agenus, Amcure, Amgen, Astellas, AstraZeneca Bayer, Beigene, Biomea, Biolnvent International AB, BMS, Boehringer, Boston Therapeutics, Celgene, Daichii Sankyo, Debiopharm, Eisai, e-Therapeutics, Exelisis, Forma Therapeutics, Genmab, GSK, Harpoon, Hutchison, Immutep, Incyte, Inovio, Iovance, Janssen, Kyowa Kirin, Lilly, Loxo, MedSir, Menarini, Merck, Merus, Millennium, MSD, Nanobiotix, Nektar, Novartis, Odonate Therapeutics, Pfizer, PharmaMar, PharmaMar, Principia, PsiOxus, Puma, Regeneron, Relay Therapeutics, Rigontec, Roche, Sanofi, Sierra Oncology, Synthon, Taiho, Takeda, Tesaro, Transgene, Turning Point Therapeutics and Upsher-Smith. S.I.O. has received consulting fees from Pfizer, Janssen, Daiichi Sankyo, Lilly and AnHeart Therapeutics; reports funding to their institution from Pfizer, Mirati, Revolution Medicine, Nuvalent, Janssen and Genentech/Roche; and reports ownership of MBrace Therapeutics and Blossomhill Therapeutics. A.P. has received consulting fees from Amgen, Bayer, Merck, Servier and Pierre Fabre; and travel, accommodation and expenses from Pierre Fabre and Bayer.

A. Sacher is a consultant and on the advisory board for Genentech-Roche and AstraZeneca; and is an institutional research and clinical trial principal investigator for AstraZeneca, Amgen, Genentech-Roche, Merck, Lilly, Pfizer, Bristol Myers Squibb, GSK, Spectrum, Iovance and CRISPR Therapeutics. A. Santoro is on the advisory board for Bristol Myers Squibb, Servier, Gilead, Pfizer, Eisai, Bayer and MSD; is a consultant for Sanofi and Incyte; and is on the speaker's bureau for Takeda, Bristol Myers Squibb, Roche, Abbvie, Amgen, Celgene, Servier, Gilead, AstraZeneca, Pfizer, ArQule, Lilly, Sandoz, Eisai, Novartis, Bayers and MSD. R.S. has been a lecturer for Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Genentech, Gilead, Merck, MSD, Moderna, Novartis, Pfizer, Roche, Sanofi and Takeda. S.U. is on the advisory board for Eisai, AstraZeneca and IgM Biosciences; and reports funding to their institution from AbbVie, Adlai Nortye, ArQule, AstraZeneca, Atreca, Boehringer Ingelheim, Bristol Myers Squibb, Celgene Corporation, Ciclomed, Erasca, Evelo Biosciences, Exelisis, G1 Therapeutics, GSK, IGM Biosciences, Incyte, Isofol, Klus Pharma, MacroGenics, Merck, Mersana Therapeutics, OncoMed Pharmaceuticals, Pfizer, Regeneron, Revolution Medicines, Synermore Biologics, Takeda, Tarveda Therapeutics, Tesaro, Tempest, and Vigeo Therapeutics. K.A. has received personal financial compensation for advisory board participation from Amgen, Novartis, AstraZeneca, G1 Therapeutics and Sanofi-Genzyme; and reports financial support to their institution for conduct related to clinical trials from Genentech, Mirati and Revolution Medicines. P.L. has served on the advisory boards of Abbvie, GenMab, Genentech, CytomX, Takeda, Cybrexa, Agenus, IQVIA, TRIGR, Pfizer, ImmunoMet, Black Diamond, GSK, QED Therapeutics, AstraZeneca, EMD Serono, Shattuck, Astellas, Salarius, Silverback, MacroGenics, Kyowa Kirin Pharmaceutical Development, Kineta, Zentalis Pharmaceuticals, Molecular Templates, STCube Pharmaceuticals, Bayer, I-Mab, Seagen, imCheck, Relay Therapeutics, Stemline, Compass BADX, Mekanist, Mersana Therapeutics, BAKX Therapeutics, Scenic Biotech, Qualigen, NeuroTrials and Actuate Therapeutics; has served on the data safety monitoring board for Agios, Five Prime, Halozyme and Tyme; and has served as a consultant for Roche-Genentech, SOTIO, SK Life Science and Roivant Sciences. J.L. reports honoraria from Targeted Oncology, Physicians' Education Resource, VJ Oncology, CancerGRACE and Community Cancer Education; advisory board participation from AstraZeneca and Astellas; research support to their institution from Erasca, Genentech, Kronos Bio, Novartis and Revolution Medicines; personal fees from Erasca, Blueprint Medicines and Daiichi Sankyo; and reports that a patent filed by Memorial Sloan Kettering Cancer Center related to multimodal features to predict response to immunotherapy (PCT/US2023/115872) is pending. M.R.P. is on the leadership board of ION Pharma; has received honoraria from Janssen Oncology; has a consulting or advisory role at Olema Pharmaceuticals, Daiichi Sankyo/UCB Japan and Accutar Biotech; and reports funding to their institution from Acerta Pharma, ADC Therapeutics, Agenus, Aileron Therapeutics, AstraZeneca, BioNTech AG, Boehringer Ingelheim, Celgene, CicloMed, Clovis Oncology, Cyteir Therapeutics, Daiichi Sankyo, Lilly, Evelo Therapeutics, Genentech/Roche, Gilead Sciences, GSK, H3 Biomedicine, Hengrui Therapeutics, Hutchison MediPharma, Jacobio, Janssen, Klus Pharma, Kymab, Loxo, LSK Biopartners, Lycera, MacroGenics, Merck, Millenium, Mirati Therapeutics, Moderna Therapeutics, Pfizer, Prelude Therapeutics, Ribon Therapeutics, Seven and Eight Biopharmaceuticals, Syndax, Taiho Pharmaceutical, Tesaro, TopAlliance BioSciences, Vigeo, ORIC Pharmaceuticals, Artios, Treadwell Therapeutics, Mabspace, IgM Biosciences, Puretech, BioTheryX, Black Diamond Therapeutics, NGM Biopharmaceuticals, Novartis, Nurix, Relay Therapeutics, Samumed, Silicon Therapeutics, TeneoBio, Zymeworks, Olema, Adagene, Astellas, NGM, Accutar Biotech, Compugen, Immunogen, Blueprint Pharmaceuticals, Bicycle Therapeutics, Cullinan Oncology, Erasca, Immune-Onc Therapeutics, Immunitas, Jazz Pharmaceuticals, Pionyr, Revolution Medicines, Step

Pharma, Syndax, Synthorx, Xencor, Bristol Myers Squibb/Celgene, Incytes, Kineta, Hotspot Therapeutics, Conjupro Biotherapeutics and Allorion Therapeutics. Y.C., Z.S., S.M., M.T.L., S.R.J., J.C., T.J., N.V.D. and J.L.S. are employees of Genentech and are Roche stockholders. S.W.H. has received honoraria from IMBdx and Ono Pharmaceutical; and reports funding to their institution from IMBdx, Hanmi, Loxo, Roche, Genentech, Mirati Therapeutics, Turnstone Bio, Arcus Biosciences, MSD, BeyondBio, Jeil Pharmaceutical, Janssen, Seagen, Lilly, MedImmune and Leap Therapeutics. The other authors declare no completing interests.

### Additional information


**Extended data** is available for this paper at <https://doi.org/10.1038/s41591-023-02696-8>.

**Supplementary information** The online version contains supplementary material available at <https://doi.org/10.1038/s41591-023-02696-8>.

**Correspondence and requests for materials** should be addressed to Jayesh Desai or Sae-Won Han.

**Peer review information** *Nature Medicine* thanks David Hong, Pashtoon Kasi, and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Primary Handling Editor: Saheli Sadanand, in collaboration with the *Nature Medicine* team.

**Reprints and permissions information** is available at [www.nature.com/reprints](http://www.nature.com/reprints).



**Extended Data Fig. 1 | Mean (SD) Plasma Concentration-Time Profiles of Divarasib as a Single Agent and in Combination with Cetuximab Following Multiple Doses.** Multiple-dose pharmacokinetic profile of divarasib was obtained on either CID8 or C2D1 from blood samples collected over an 8 hour period following administration of divarasib 400 mg QD (n = 76 patients)<sup>1</sup> or

divarasib 400 mg QD plus 250 mg/m<sup>2</sup> of cetuximab QW (n = 21 patients). Time (hr) is shown as nominal time and the error bars represent standard deviation around the mean divarasib plasma concentration (ng/mL) measured at each time point during the 8 hour post-dose interval.

## Extended Data Table 1 | All TRAEs

	TRAEs	Grade 3-4 <sup>†</sup> TRAEs
Total number of patients with at least one AE, n (%)	29 (100)	13 (44.8)
Diarrhea	24 (82.8)	3 (10.3)
Nausea	21 (72.4)	0
Rash*	28 (96.6)	2 (6.9)
Vomiting	14 (48.3)	0
Dry skin	10 (34.5)	1 (3.4)
Paronychia	6 (20.7)	1 (3.4)
Hypomagnesaemia	4 (13.8)	2 (6.9)
Pruritus	4 (13.8)	1 (3.4)
Infusion-related reaction	4 (13.8)	1 (3.4)
Asthenia	4 (13.8)	0
Fatigue	4 (13.8)	0
Abdominal pain	3 (10.3)	1 (3.4)
Amylase increased	3 (10.3)	0
Pyrexia	3 (10.3)	0
Dysgeusia	3 (10.3)	0
Lipase increased	2 (6.9)	2 (6.9)
Abdominal pain upper	2 (6.9)	1 (3.4)
Headache	2 (6.9)	1 (3.4)
Mucosal inflammation	2 (6.9)	0
Conjunctivitis	2 (6.9)	0
Decreased appetite	2 (6.9)	0
Aspartate aminotransferase increased	2 (6.9)	0
Alanine aminotransferase increased	2 (6.9)	0
Insomnia	1 (3.4)	1 (3.4)
Neutrophil count decreased	1 (3.4)	1 (3.4)
White blood cell count decreased	1 (3.4)	1 (3.4)
Dry eye	1 (3.4)	0
Dry mouth	1 (3.4)	0
Hot flush	1 (3.4)	0
Nail infection	1 (3.4)	0
Blepharitis	1 (3.4)	0

Catheter site rash	1 (3.4)	0
Eczema eyelids	1 (3.4)	0
Hypertrichosis	1 (3.4)	0
Hypoaesthesia	1 (3.4)	0
Mouth ulceration	1 (3.4)	0
Nail disorder	1 (3.4)	0
Onycholysis	1 (3.4)	0
Oral dysaesthesia	1 (3.4)	0
Otitis externa	1 (3.4)	0
Otitis media	1 (3.4)	0
Pancreatitis	1 (3.4)	0
Skin exfoliation	1 (3.4)	0
Urticaria	1 (3.4)	0
Skin fissures	1 (3.4)	0
Paraesthesia	1 (3.4)	0
Vision blurred	1 (3.4)	0
Pain in extremity	1 (3.4)	0
Hyponatraemia	1 (3.4)	0
Neuropathy peripheral	1 (3.4)	0
Abdominal distension	1 (3.4)	0
Activated partial thromboplastin time prolonged	1 (3.4)	0
Myalgia	1 (3.4)	0
Weight decreased	1 (3.4)	0
Dizziness	1 (3.4)	0
Dyspepsia	1 (3.4)	0
Arthralgia	1 (3.4)	0
Constipation	1 (3.4)	0
Cough	1 (3.4)	0
Gastroesophageal reflux disease	1 (3.4)	0
Edema peripheral	1 (3.4)	0

AE, adverse event.

\*Rash Grouped Terms: dermatitis acneiform, rash, rash pustular, rash follicular, and rash maculo-papular.

<sup>†</sup>No grade 5 TRAEs reported.

**Extended Data Table 2 | Pharmacokinetic parameters of divarasib in combination with cetuximab following multiple doses**

Divarasib Treatment (400 mg QD) <sup>a</sup>	N	$t_{\max}$ (hr)	$C_{\max}$ (ng/mL)	$AUC_{0-24}$ (hr*ng/mL)	$R_{AUC0-24}$ <sup>b</sup> (fold)
Single agent <sup>11</sup>	76	2.0 (0.5-8.0)	657 ± 185	9130 ± 3160	1.4 ± 0.4
Combination with cetuximab (250 mg/m <sup>2</sup> QW)	21	3.0 (1.0-4.0)	689 ± 208	9600 ± 2890	1.2 ± 0.4

$AUC_{0-24}$ , area under the concentration-time curve from 0 to 24 hours;  $C_{\max}$ , maximum concentration; N, number of subjects with evaluable pharmacokinetic data; QD, once daily; QW, once weekly;  $R_{AUC0-24}$ , accumulation ratio based on  $AUC_{0-24}$ ;  $t_{\max}$ , time to maximum concentration.

<sup>a</sup> Multiple-dose pharmacokinetics were evaluated on either C1D8 or C2D1. C1D8 or C2D1  $AUC_{0-24}$  calculations included imputation of the 24-hour time point based on predose C1D8 or C2D1 plasma concentration of divarasib.

<sup>b</sup> n=63 and n=21 for single-agent divarasib and divarasib plus cetuximab cohorts, respectively.  $R_{AUC0-24}$  is defined as C1D8 or C2D1  $AUC_{0-24}$  / C1D1  $AUC_{0-24}$ . Thirteen patients who did not have a C1D1  $AUC_{0-24}$  were excluded from the calculation of  $R_{AUC0-24}$ .

Pharmacokinetic data from capsule and tablet formulations were pooled for this analysis. Analysis was performed with nominal time.  $T_{\max}$  is presented as median (range). All other statistics are presented as the mean ± s.d. Concentration values below the lower limit of quantification (BLQ) before administration of the first dose were set to 0 and concentration values (BLQ) after administration of the first dose administration were set to half the lower limit of quantification. Participants with dose reductions/interruptions were excluded from steady-state pharmacokinetic parameter analyses.

## Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

### Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed

- The exact sample size ( $n$ ) for each experimental group/condition, given as a discrete number and unit of measurement
- A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided  
*Only common tests should be described solely by name; describe more complex techniques in the Methods section.*
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g.  $F$ ,  $t$ ,  $r$ ) with confidence intervals, effect sizes, degrees of freedom and  $P$  value noted  
*Give  $P$  values as exact values whenever suitable.*
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen's  $d$ , Pearson's  $r$ ), indicating how they were calculated

*Our web collection on [statistics for biologists](#) contains articles on many of the points above.*

### Software and code

Policy information about [availability of computer code](#)

Data collection

Data analysis

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

### Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

For eligible studies qualified researchers may request access to individual patient level clinical data through a data request platform. At the time of writing this request platform is Vivli: <https://vivli.org/ourmember/roche/>. Requests for access to Roche data are made through the Vivli process and supported by a research proposal that is assessed by an Independent Review Panel. The panel considers the scientific merit of each application. On average it takes a few months to access data in the Vivli platform, but the timeline will vary depending on the number of data contributors, the number of studies, and your availability to respond to



comments. Analyses performed on the data must be in line with the purpose outlined in the research proposal and be approved by the Independent Review Panel.

For up to date details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here: <https://www.roche.com/innovation/process/clinical-trials/data-sharing>. Anonymized records for individual patients across more than one data source external to Roche can not, and should not, be linked due to a potential increase in risk of patient re-identification.

## Human research participants

Policy information about [studies involving human research participants and Sex and Gender in Research](#).

Reporting on sex and gender	Sex is reported per protocol
Population characteristics	Reported in Table 1
Recruitment	Patients with colorectal cancer were recruited from clinics at participating institutions from 17 sites in 10 countries. These sites were selected based on factors such as patient population availability and expertise. Patients were recruited, screened, and enrolled at the discretion of the investigator. All patients had local or central blood-based genomic screening that informed eligibility. Attempts to limit bias through study design and site selection were made to create a representative population of patients with CRC, but are limited by this study's small sample size.
Ethics oversight	This study was conducted in full conformance with the ICH E6 guideline for Good Clinical Practice and the Declaration of Helsinki, or the applicable laws and regulations of the country in which the research is conducted, whichever affords the greater protection to the individual. The protocol was approved by the institutional review boards at City of Hope Comprehensive Cancer Center, Princess Margaret Cancer Center, Peter MacCallum Cancer Center, Jewish General Hospital, Universitair Medisch Centrum Utrecht, Biokinetica Przychodnia Jozefow, Istituto Scientifico Romagnolo per lo Studio y la Cura dei Tumori, Asst Grande Ospedale Metropolitano Niguarda, UZ Antwerpen, Hospital Universitario Virgen Del Rocio, Hospital Universitari Vall D'hebron, Seoul National University Hospital, Seoul National University Bundang Hospital, Hospital Clinico Universitario De Valencia, Hospital Universitario 12 De Octubre, Sheba Medical Center, and Abramson Cancer Center. Patients provided signed informed consent prior to enrollment.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

## Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences  Behavioural & social sciences  Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://nature.com/documents/nr-reporting-summary-flat.pdf)

## Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	The study planned to enroll approximately 29 patients in the cetuximab combination cohorts. GO42144 was intended to obtain preliminary safety, PK and activity information and the sample sizes do not reflect any power and type I considerations. However, the expansion sample size is sufficient to provide a meaningful likelihood of observing adverse events occurring at appreciable frequency (5% or higher) and to assess preliminary anti-tumor activity. Details regarding the probability of safety-signal detection with an expansion cohort of 20 patients can be found in Section 6.1.2 of the protocol.
Data exclusions	This analysis included all patients who received at least one dose of divarasib and cetuximab; response rates were reported for patients with measurable disease at baseline
Replication	Replication is not applicable to a clinical trial, as this study was conducted with human participants.
Randomization	This was a non-randomized Phase 1 study where patients were enrolled directly into the divarasib plus cetuximab treatment arm.
Blinding	This was an open-label single-arm study

## Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

## Materials &amp; experimental systems

## Methods

n/a	Involvement
<input checked="" type="checkbox"/>	<input type="checkbox"/> Involved in the study
<input checked="" type="checkbox"/>	<input type="checkbox"/> Antibodies
<input checked="" type="checkbox"/>	<input type="checkbox"/> Eukaryotic cell lines
<input checked="" type="checkbox"/>	<input type="checkbox"/> Palaeontology and archaeology
<input checked="" type="checkbox"/>	<input type="checkbox"/> Animals and other organisms
<input type="checkbox"/>	<input checked="" type="checkbox"/> Clinical data
<input checked="" type="checkbox"/>	<input type="checkbox"/> Dual use research of concern

n/a	Involvement
<input checked="" type="checkbox"/>	<input type="checkbox"/> Involved in the study
<input checked="" type="checkbox"/>	<input type="checkbox"/> ChIP-seq
<input checked="" type="checkbox"/>	<input type="checkbox"/> Flow cytometry
<input checked="" type="checkbox"/>	<input type="checkbox"/> MRI-based neuroimaging

## Clinical data

Policy information about [clinical studies](#)

All manuscripts should comply with the ICMJE [guidelines for publication of clinical research](#) and a completed [CONSORT checklist](#) must be included with all submissions.

Clinical trial registration	ClinicalTrials.gov: NCT04449874
Study protocol	Included in the Supplementary Information.
Data collection	A total of 29 patients were enrolled into Arm C from 17 sites in 10 countries between 28 July 2021 and 07 October 2022. Health care professionals at the clinical trial sites collected samples and recorded data into EDC systems.
Outcomes	<p>The primary objective of this study was to evaluate safety; secondary objectives included characterization of preliminary antitumor activity and the pharmacokinetic profile, and exploratory objectives include the characterization of biomarkers of response and resistance.</p> <p>Safety was assessed through the evaluation of adverse events (NCI CTCAE v5.0), changes in laboratory test results, and changes in vital signs and ECGs, and included all patients who received at least one dose of both study drugs. Preliminary antitumor activity was determined by the investigator according to RECIST v1.1. Confirmed ORR was defined as the proportion of patients with measurable disease at baseline with CR or PR on two consecutive tumor assessments at least 4 weeks apart, while the best response did not require a confirmatory assessment. PFS was defined as the time from first treatment to the first occurrence of disease progression or death from any cause during the study (whichever occurred first). Pharmacokinetic parameters were estimated using non-compartmental analysis of concentration-time data. Retrospective ctDNA profiling was conducted with longitudinal plasma samples collected at baseline, on-treatment and end-of-treatment visits. To explore the mechanisms of potential acquired resistance, we conducted ctDNA profiling from paired baseline and disease progression/end-of-treatment plasma samples.</p>